Francois Nader, MD, has been president, chief executive officer and a member of the Board of Directors of NPS Pharmaceuticals since 2008. During his tenure, Dr. Nader transformed NPS into a leading global biotechnology company focused on treatments for patients with rare disorders in gastroenterology and endocrinology. NPS’ lead product, Gattex for Short Bowel Syndrome, was approved in Europe and the US in 2012. NPS plans to file its second product, Natpara for Hypoparathyroidism, in the US in 2013.

Dr. Nader is a 30-year veteran of the healthcare industry. He joined NPS in 2006 as chief medical and commercial officer and was promoted to chief operating officer in 2007. Previously, he was a venture partner at Care Capital. Dr. Nader served on the North America Leadership Team of Aventis and its predecessor companies and held a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Prior, Dr. Nader led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.

Dr. Nader currently serves as chairman of the Board of Trustees for BioNJ, New Jersey’s trade organization representing the biotechnology industry, and Board member of the New Jersey Chamber of Commerce. He formerly served on the Board of the Healthcare Institute of New Jersey and Noven Pharmaceuticals.

Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee.

Pharmaceutical, Health, Healthcare, Medicine, Biotechnology, CEO, Chief Executive Officer (CEO), Ties to MD, President, Biology